Document is current

Article History

Received: 11 June 2019

Revised: 4 November 2019

Accepted: 5 November 2019

First Online: 10 December 2019

Competing interests

: The authors declare no competing interests.

: The authors confirm that the study have been conducted within appropriate ethical guidelines and legislation. The local ethics committee in Umeå approved the study, and all patients gave their informed consent to participate in the study (09–199 M). The trial was permitted by the Swedish Medical Product Agency, EudraCT number: 2010-018281-23, registered 4 January 2010,.

: This study was supported by the Swedish Cancer Society (A.T.B., H.A.), Umeå University Hospital (A.T.B.), the Swedish Research Council (H.A.), the Cancer Research Foundation in Northern Sweden (B.B.), the Research Foundation of Clinical Neuroscience, Umeå University (A.T.B.) and by the regional agreement between Umeå University and Västerbotten County Council on the cooperation in the field of Medicine, Odontology and Health (A.T.B.).

: Summarised datasets supporting the conclusions of this article are included within the article and as additional .